American Journal of Pharmacogenomics

, Volume 1, Issue 4, pp 271–281 | Cite as

Drug Target Pharmacogenomics

An Overview
Genomics in Drug Development


Pharmacogenomics is a field aimed at understanding the genetic contribution to variability in drug efficacy and toxicity. The goal is to be able to select the drugs with the greatest likelihood of benefit and the least likelihood of harm in individual patients, based on their genetic make-up. Pharmacogenetics has historically been a field focused primarily on genetic polymorphisms in drug metabolizing enzymes and their impact on drug efficacy and toxicity. More recently, investigators have begun to study the relationship between drug target polymorphisms and drug efficacy and toxicity.

There are now numerous examples in the literature of associations between drug target polymorphisms and drug effect. Drug targets can be broken into three main categories: the direct protein target of the drug, signal transduction cascades or downstream proteins, and disease pathogenesis proteins. While the drug target pharmacogenetics literature provides ‘proof of concept’ that genetic variability contributes to the variability in drug response, the data are not to the point of being clinically useful in most cases. Specific problems to date include the inability of a single polymorphism to be highly predictive of response, and inconsistencies across studies of the same polymorphism. It seems likely that an important factor in the above limitations is the approach of focusing on a single polymorphism in a single gene. Given that most drug responses involve a large number of proteins, all of whose genes could have several polymorphisms, it seems unlikely that a single polymorphism in a single gene would explain a high degree of drug response variability in a consistent fashion. Thus, it seems that a polygenic, or genomic approach will be more appropriate. Candidate gene and genome scanning approaches to pharmacogenomics have shown promise in relating drug target polymorphisms to response or toxicity, and pharmacogenomic strategies for drug discovery and drug development are now being implemented by most major pharmaceutical companies. Pharmacogenomics has the potential to significantly enhance the ability of clinicians to use medications in a safe and effective manner and, as such, represents an exciting field with tremendous clinical potential.



Supported in part by NIH HL64691, HL65729 and HL64924.


  1. 1.
    Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for inter-individual differences in drug response. Ann Rev Genomics Hum Genet 2001; 2: 9–39CrossRefGoogle Scholar
  2. 2.
    Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487–91PubMedCrossRefGoogle Scholar
  3. 3.
    Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405(6788): 857–65PubMedCrossRefGoogle Scholar
  4. 4.
    Shi MM, Bleavins MR, de la Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos 2001; 29 (4 Pt 2): 591–5PubMedGoogle Scholar
  5. 5.
    Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7(5): 201–4PubMedCrossRefGoogle Scholar
  6. 6.
    Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenoceptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97(19): 10483–8PubMedCrossRefGoogle Scholar
  7. 7.
    Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human beta 2-adrenoceptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33(32): 9414–9PubMedCrossRefGoogle Scholar
  8. 8.
    McGraw DW, Forbes SL, Kramer LA, et al. Polymorphisms of the 5′ leader cistron of the human beta2-adrenoceptor regulate receptor expression. J Clin Invest 1998; 102(11): 1927–32PubMedCrossRefGoogle Scholar
  9. 9.
    Jacobsen P, Rossing K, Rossing P, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998; 53(4): 1002–6PubMedCrossRefGoogle Scholar
  10. 10.
    Kohno M, Yokokawa K, Minami M, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106(5): 544–9PubMedCrossRefGoogle Scholar
  11. 11.
    Ohmichi N, Iwai N, Uchida Y, et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10(8): 951–5PubMedCrossRefGoogle Scholar
  12. 12.
    Okamura A, Ohishi M, Rakugi H, et al. Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999; 50(10): 811–22PubMedCrossRefGoogle Scholar
  13. 13.
    Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998; 47(9): 1507–11PubMedCrossRefGoogle Scholar
  14. 14.
    Perna A, Ruggenenti P, Testa A, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000; 57(1): 274–81PubMedCrossRefGoogle Scholar
  15. 15.
    Stavroulakis GA, Makris TK, Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14(4): 427–32PubMedCrossRefGoogle Scholar
  16. 16.
    Prasad A, Narayanan S, Husain S, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000; 102(1): 35–41PubMedCrossRefGoogle Scholar
  17. 17.
    Sasaki M, Oki T, Iuchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996; 14(12): 1403–8PubMedCrossRefGoogle Scholar
  18. 18.
    Ha SK, Yong Lee S, Su Park H, et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000; 15(10): 1617–23PubMedCrossRefGoogle Scholar
  19. 19.
    Takahashi T, Yamaguchi E, Furuya K, et al. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med 2001; 95(2): 130–5PubMedCrossRefGoogle Scholar
  20. 20.
    Cockcroft JR, Gazis AG, Cross DJ, et al. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36(3): 371–5PubMedCrossRefGoogle Scholar
  21. 21.
    Gratze G, Fortin J, Labugger R, et al. Beta-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999; 33(6): 1425–30PubMedCrossRefGoogle Scholar
  22. 22.
    Hoit BD, Suresh DP, Craft L, et al. Beta-2 adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000; 139(3): 537–42PubMedGoogle Scholar
  23. 23.
    Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta-2 adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162(1): 75–80PubMedGoogle Scholar
  24. 24.
    Lima JJ, Thomason DB, Mohamed MHN, et al. Impact of genetic polymorphisms of the beta-2 adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65(5): 519–25PubMedCrossRefGoogle Scholar
  25. 25.
    Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100(12): 3184–8PubMedCrossRefGoogle Scholar
  26. 26.
    Tan S, Hall IP, Dewar J, et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350(9083): 995–9PubMedCrossRefGoogle Scholar
  27. 27.
    Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101(9): 1013–8PubMedCrossRefGoogle Scholar
  28. 28.
    Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22(2): 168–70PubMedCrossRefGoogle Scholar
  29. 29.
    Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P, et al. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol (Oxf) 2000; 52(5): 581–5CrossRefGoogle Scholar
  30. 30.
    Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47(4): 598–605PubMedCrossRefGoogle Scholar
  31. 31.
    Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response [letter]. Lancet 2000; 355(9215): 1615–6PubMedCrossRefGoogle Scholar
  32. 32.
    Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21(1): 17–27PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen BM, Ennulat DJ, Centorrino F, et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology Berl 1999; 141(1): 6–10PubMedCrossRefGoogle Scholar
  34. 34.
    Eichhammer P, Albus M, Borrmann-Hassenbach M, et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen’s study on DRD3 and tardive dyskinesia. Am J Med Genet 2000; 96(2): 187–91PubMedCrossRefGoogle Scholar
  35. 35.
    Hwu HG, Hong CJ, Lee YL, et al. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 1998; 44(6): 483–7PubMedCrossRefGoogle Scholar
  36. 36.
    Kaiser R, Konneker M, Henneken M, et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000; 5(4): 418–24PubMedCrossRefGoogle Scholar
  37. 37.
    Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur Neuropsychopharmacol 1999; 10(1): 17–20PubMedCrossRefGoogle Scholar
  38. 38.
    Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000; 10(4): 335–41PubMedCrossRefGoogle Scholar
  39. 39.
    Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24(2): 141–6PubMedGoogle Scholar
  40. 40.
    Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics 2000; 10(1): 43–8PubMedCrossRefGoogle Scholar
  41. 41.
    Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19(2): 123–32PubMedCrossRefGoogle Scholar
  42. 42.
    Yu YW, Tsai SJ, Lin CH, et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999; 10(6): 1231–3PubMedCrossRefGoogle Scholar
  43. 43.
    Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3(6): 508–11PubMedCrossRefGoogle Scholar
  44. 44.
    Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11(1): 215–9PubMedCrossRefGoogle Scholar
  45. 45.
    Whale R, Quested DJ, Laver D, et al. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology Berl 2000; 150(1): 120–2PubMedCrossRefGoogle Scholar
  46. 46.
    McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15(5): 410–7PubMedCrossRefGoogle Scholar
  47. 47.
    Cannella G, Paoletti E, Barocci S, et al. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 1998; 54(2): 618–26PubMedCrossRefGoogle Scholar
  48. 48.
    Hernandez D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58(2): 889–97PubMedCrossRefGoogle Scholar
  49. 49.
    Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients [see comments]. Mol Psychiatry 1997; 2(2): 139–45PubMedCrossRefGoogle Scholar
  50. 50.
    Owen RJ, Slater ER, Gibson J, et al. Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. Microb Drug Resist 1999; 5(2): 141–6PubMedCrossRefGoogle Scholar
  51. 51.
    Vahey M, Nau ME, Barrick S, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol 1999; 37(8): 2533–7PubMedGoogle Scholar
  52. 52.
    Mukae S, Aoki S, Itoh S, et al. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36(1): 127–31PubMedCrossRefGoogle Scholar
  53. 53.
    Jia H, Hingorani AD, Sharma P, et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34(1): 8–14PubMedCrossRefGoogle Scholar
  54. 54.
    Turner ST, Schwartz GL, Chapman AB, et al. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37 (2 Part 2): 739–43PubMedCrossRefGoogle Scholar
  55. 55.
    Zill P, Baghai TC, Zwanzger P, et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment [In Process Citation]. Neuroreport 2000; 11(9): 1893–7PubMedCrossRefGoogle Scholar
  56. 56.
    Brandt JT, Isenhart CE, Osborne JM, et al. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74(6): 1564–72PubMedGoogle Scholar
  57. 57.
    Steen VM, Lovlie R, Osher Y, et al. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic- depressive illness. Pharmacogenetics 1998; 8(3): 259–68PubMedGoogle Scholar
  58. 58.
    Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19(3): 700–3PubMedCrossRefGoogle Scholar
  59. 59.
    Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338(25): 1793–7PubMedCrossRefGoogle Scholar
  60. 60.
    Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11(6): 691–6PubMedCrossRefGoogle Scholar
  61. 61.
    Drici MD, Barhanin J. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie 2000; 55(1): 185–93PubMedGoogle Scholar
  62. 62.
    Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97(2): 175–87PubMedCrossRefGoogle Scholar
  63. 63.
    Escande D. Pharmacogenetics of cardiac K(+) channels. Eur J Pharmacol 2000; 410(2–3): 281–7PubMedCrossRefGoogle Scholar
  64. 64.
    Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101(12): 1366–71PubMedCrossRefGoogle Scholar
  65. 65.
    Nemeth A, Szakmary K, Kramer J, et al. Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Eur J Clin Chem Clin Biochem 1995; 33(11): 799–804PubMedGoogle Scholar
  66. 66.
    Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113(2): 157–66PubMedCrossRefGoogle Scholar
  67. 67.
    Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology 1998; 50(3): 669–77PubMedCrossRefGoogle Scholar
  68. 68.
    Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338(2): 86–93PubMedCrossRefGoogle Scholar
  69. 69.
    de Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83(6): 852–6PubMedCrossRefGoogle Scholar
  70. 70.
    Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group. N Engl J Med 2000; 342(21): 1560–7PubMedCrossRefGoogle Scholar
  71. 71.
    Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001; 50(2): 224–31PubMedCrossRefGoogle Scholar
  72. 72.
    de Maat MP, Kastelein JJ, Jukema JW, et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18(2): 265–71PubMedCrossRefGoogle Scholar
  73. 73.
    Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92(26): 12260–4PubMedCrossRefGoogle Scholar
  74. 74.
    Lithell H, Berglund L, Jonsson J, et al. Prediction of blood pressure response to ACE inhibitors by using patterns of genetic variation in the RAAS [abstract]. Circulation 1999; 100(18): I–755Google Scholar
  75. 75.
    McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000; 18(5): 505–8PubMedCrossRefGoogle Scholar
  76. 76.
    Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999; 26 (4 Suppl. 12): 71–7PubMedGoogle Scholar
  77. 77.
    Schwartz RS. Racial profiling in medical research. N Engl J Med 2001; 344(18): 1392–3PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Departments of Pharmacy Practice and Medicine (Cardiology)University of FloridaGainesvilleUSA

Personalised recommendations